Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
NCT ID: NCT02798679
Last Updated: 2022-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2016-08-31
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Molecular Drivers of Cancer
NCT02470715
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
NCT06511388
Rare Tumors and Cancer Predisposition in Individuals and Families
NCT05350761
Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment
NCT06851975
Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH
NCT02552381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A treatment plan that includes anthracyclines and/or trastuzumab
* Age \>45 years
* Able to hold breath for 10 seconds
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria
* Known heart failure or LVEF \<50%
* Heart rate over 100 bpm
* Renal dysfunction with GFR \<30 mL/min/1.73m2
* Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
* Symptomatic claustrophobia
* Plans to move within 24 months of enrollment
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chetan Shenoy, MBBS
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV-2016-24434
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.